Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-14T09:20:53.558Z Has data issue: false hasContentIssue false
  • English
  • Français

Terapia electroconvulsiva en síndrome neuroléptico Maligno

Published online by Cambridge University Press:  12 May 2020

M.Z Azhar  and
S.L. Varma
M.Z Azhar
Affiliation:
Departamento de Psiquiatría, Hospital Científico Universitario de Malasia, 16150Kubang Kerian Kelantan, Malasia
S.L. Varma
Affiliation:
Departamento de Psiquiatría, Hospital Científico Universitario de Malasia, 16150Kubang Kerian Kelantan, Malasia

Resumen

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Una mujer de mediana edad que tenía psicosis maniaco depresiva desarrolló un síndrome neuroléptico maligno (SNM) con haloperidol. Se comunica aquí la resolución de la psicosis emergente después de la recuperación del SNM con un uso juicioso de terapia electroconvulsiva (TEC) seguido por reintroducción gradual de antipsicóticos.

Type
Cartas al editor
Information
European Psychiatry (Ed. Española) , Volume 2 , Issue 4 , August 1995 , pp. 267 - 268
Copyright
Copyright © European Psychiatric Association 1995

References

Bibliografía

Meltzer, HY. Rigidity, hyperpyrexia and out come following fleuphenazine enanthate. Psychophannacology 1973; 29: 337–46.Google Scholar
Peet, M, Collier, J. Use of carbamazapine in psychosis After NMS. Br J Psychiatry 1990; 156: 579–81.CrossRefGoogle Scholar
Shalev, A, Manitz, H. The neuroleptic málignant syndrome: agent andhost interaction. Acta Psychiatr Scand 1986; 73: 337–47.CrossRefGoogle ScholarPubMed
Stoudmoire, A, Lauther, JS. NMS and neuroleptic induced catatonia. Int J Psychiatry Med 1989; 14: 57–63.Google Scholar
Wells, AL, Sommi, RW, Crisman, ML. Neuroleptic rechallenge of NMS. Drug lntell Clin Pharm 1988; 22: 457–79.Google Scholar